IFNB1 and infection: Only pre-exposure to IFN-β decreased infection, and this effect was reversed by co-administration of the JAK/Stat inhibitor ruxolitinib (Fig. 2, D to E), confirming that CMs can mount an antiviral response with appropriate stimulation.